Inloggad som:

MBG453-MDS

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

MBG453-MDS
A randomized, double-blind, placebo-controlled phase II multicenter study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria
A randomized, double-blind, placebo-controlled phase II multicenter study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 2
Palliativ
Företag

Studien ändrades senast av: studysonia (2020-05-12)

Tillbaka till listan